Haemonetics (HAE) Non-Current Deferred Tax Liability (2010 - 2026)

Haemonetics has reported Non-Current Deferred Tax Liability for 17 years, with the latest figure at $38.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 72.81% year-over-year to $38.0 million; the trailing twelve-month figure through Mar 2026 stood at $38.0 million (down 72.81% YoY), and the FY2026 full-year result was $38.0 million, down 72.81% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $38.0 million, down from $56.0 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $140.0 million in Q1 2025, with the low at $26.1 million in Q1 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $56.3 million, with a median of $57.1 million recorded in 2025.
• Year-over-year, Non-Current Deferred Tax Liability surged 291.54% in 2023 and plunged 72.81% in 2026.
• Tracing HAE's Non-Current Deferred Tax Liability over 5 years: stood at $40.2 million in 2022, then surged by 55.03% to $62.2 million in 2023, then decreased by 1.28% to $61.5 million in 2024, then decreased by 8.9% to $56.0 million in 2025, then sank by 32.03% to $38.0 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $38.0 million (Q1 2026), $56.0 million (Q4 2025), and $58.2 million (Q3 2025), per Business Quant data.

Peer Comparison